Where does fedratinib fit as a treatment option for myelofibrosis?

FAQ published on January 20, 2020
Download Transcript
Rami S. Komrokji, MD
Professor of Medicine and Oncologic Sciences
University of South Florida College of Medicine
Vice Chair, Malignant Hematology Department
Moffitt Cancer Center
Tampa, Florida
Where does fedratinib fit as a treatment option for myelofibrosis?

For patients that experience ruxolitinib failure, that's definitely an option. Ruxolitinib failure is defined usually as having at least three months of adequate trial of the ruxolitinib and failure to have spleen reduction or symptom improvement, or if patients had the response, losing that response. Intolerance is defined with having at least one month of ruxolitinib and developing cytopenias that require transfusions. So in that setting, around 30% of the patients did benefit from fedratinib.

Last modified: January 20, 2020